Structure-activity relationship of bis-galloyl derivatives related to (-)-epigallocatechin gallate

Chemical and Pharmaceutical Bulletin

Volumn 57, Issue 2, 2009, Pages 190-194

  Dodo, Kosuke ^a,b   Minato, Taro ^a   Hashimoto, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

( ) epigallocatechin gallate; Antiproliferative activity; Gallic acid

Indexed keywords

12 (3 HYDROXYBENZOYLOXY)DODECYL 3,4,5 TRIHYDROXYBENZOATE; 12 (3,4 DIHYDROXYBENZOYLOXY)DODECYL 3,4,5 TRIHYDROXYBENZOATE; 12 (3,4,5 TRIHYDROXYBENZOYLOXY)DODECYL 3,4,5 TRIHYDROXYBENZOATE; 12 (4 HYDROXYBENZOYLOXY)DODECYL 3,4,5 TRIHYDROXYBENZOATE; 12 BENZOYLOXYDODECYL 3,4,5 TRIHYDROXYBENZOATE; 2 (3,4,5 TRIHYDROXYBENZOYLOXY)ETHYL 3,4,5 TRIHYDROXYBENZOATE; 6 (3,4,5 TRIHYDROXYBENZOYLOXY)HEXYL 3,4,5 TRIHYDROXYBENZOATE; BIS GALLAMIDE DERIVATIVE; BIS GALLIC ACID DERIVATIVE; BIS GALLOYL DERIVATIVE; CASPASE 3; EPIGALLOCATECHIN GALLATE; GALLAMIDE DERIVATIVE; GALLIC ACID DERIVATIVE; GREEN TEA EXTRACT; N [12 (3,4,5 TRIHYDROXYBENZAMIDO)DODECYL] 3,4,5 TRIHYDROXYBENZAMIDE; N [2 (3,4,5 TRIHYDROXYBENZAMIDO)ETHYL] 3,4,5 TRIHYDROXYBENZAMIDE; N [6 (3,4,5 TRIHYDROXYBENZAMIDO)HEXYL] 3,4,5 TRIHYDROXYBENZAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ASSAY; HUMAN; HUMAN CELL; IC 50; MITOSIS INHIBITION; STRUCTURE ACTIVITY RELATION; TEA;

ANTICARCINOGENIC AGENTS; CASPASE 3; CATECHIN; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, THIN LAYER; ENZYME ACTIVATION; HL-60 CELLS; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE-ACTIVITY RELATIONSHIP; TEA;

EID: 61449114953     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.57.190     Document Type: Article

References (8)

1. Nakachi K., Matsuyama S., Miyake S., Suganuma M., Imai K., Bio- factors, 13, 49-54 (2000).
2. Fujiki H., Suganuma M., Imai K., Nakachi K., Cancer Lett., 188, 9-13 (2002).
3. Fujiki H., Okuda T., Drugs Future, 17, 462-164 (1992).
4. Komori A., Yatsunami J., Okabe S., Abe S., Hara K., Suganuma M, Kim S.-J., Fujiki H., Jpn. J. Clin. Oncol., 23, 186-190 (1993).
5. Fujiki H., Suganuma M., Proc. Jpn. Acad., 78, 263-270 (2002).
6. Okabe S., Suganuma M., Hayashi M., Sueoka E., Komori A., Fujiki H., Jpn. J. Cancer Res., 88, 639-643 (1997).
7. Dodo K., Minato T., Noguchi-Yachide T., Suganuma M., Hashimoto Y., Bioorg. Med. Chem., 16, 7975-7982 (2008).
8. Ren Y., Himmeldirk K., Chen X., J. Med. Chem., 49, 2829-2837 (2006).